CastleKeep Investment Advisors
SUPN icon

CastleKeep Investment Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

CastleKeep Investment Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50,130
Closed -$2.49M – 86
2025
Q4 		$2.49M Hold
50,130
– – 1.13% 22
2025
Q3 		$2.4M Buy
50,130
+10,065
+25% +$405K 1.12% 21
2025
Q2 		$1.26M Buy
+40,065
New +$1.28M 0.62% 51

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CastleKeep Investment Advisors's SUPN Position: Q1 2026 in Review

CastleKeep Investment Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 50,130 shares — an estimated $2.49M sold.

CastleKeep Investment Advisors first reported a position in SUPN in Q2 2025 and held it in 3 quarters. The position peaked at $2.49M in Q4 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • CastleKeep Investment Advisors reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • CastleKeep Investment Advisors sold 50,130 Supernus Pharmaceuticals shares in Q1 2026, an estimated $2.49M.
  • CastleKeep Investment Advisors first reported a position in Supernus Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • CastleKeep Investment Advisors's Supernus Pharmaceuticals position peaked at $2.49M in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on CastleKeep Investment Advisors's 13F filing for Q1 2026, filed 11 May 2026.